• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by British American Tobacco Industries p.l.c.

    8/1/25 10:03:02 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BTI alert in real time by email
    S-8 1 forms-8.htm REGISTRATION STATEMENT
    As filed with the Securities and Exchange Commission on August 1, 2025

    Registration No. 333-[●]

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT
    UNDER THE SECURITIES ACT OF 1933

    British American Tobacco p.l.c.
    (Exact Name of Registrant as Specified in Its Charter)

    England and Wales
    (State or Other Jurisdiction
    of Incorporation or Organization)
     
    98-0207762
    (I.R.S. Employer Identification No.)

    Globe House
    4 Temple Place
    London WC2R 2PG
    United Kingdom
    +44 (0) 20 7845 1000
    (Address of Principal Executive Offices, Including Zip Code)

    British American Tobacco Restricted Share Plan
    British American Tobacco Performance Share Plan
    (Full Title of the Plans)

    Puglisi & Associates
    850 Library Avenue
    Suite 204
    Newark, DE 19711
    (Name and Address of Agent for Service)

    (302) 738-6680
     (Telephone Number, Including Area Code, of Agent For Service)

    Copy to:

    Alyssa K. Caples
    Cravath, Swaine & Moore LLP
    100 Cheapside
    London EC2V 6DT
    United Kingdom
    +44 (0)20 7453 1000



    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☒
    Accelerated filer
    ☐
           
    Non-accelerated filer
    ☐ (Do not check if a smaller reporting company)
    Smaller reporting company
    ☐
           
    Emerging growth company
    ☐
       

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐
     

    EXPLANATORY NOTE

    British American Tobacco p.lc., a public limited company incorporated under the laws of England and Wales (the “Registrant”), is filing this Registration Statement on Form S-8 (the “Registration Statement”) to register (a) an additional 4,000,000 ordinary shares, nominal value 25 pence per share (the “Ordinary Shares”), initially represented by American depositary shares (each of which represents one Ordinary Share) (“ADSs”), that may be offered and sold under the British American Tobacco Restricted Share Plan (the “Restricted Share Plan”) and (b) 2,000,000 Ordinary Shares, initially represented by ADSs, that may be offered and sold under the British American Tobacco Performance Share Plan (the “Performance Share Plan” and, together with the Restricted Share Plan, the “Plans”).

    The ADSs may be represented by American depositary receipts. A separate registration statement on Form F-6 has been or will be filed with the Securities and Exchange Commission (the “Commission”) registering the ADSs.

    On March 16, 2020, the Registrant filed a Registration Statement on Form S-8 (File No. 333-237186) with the Commission to register 4,000,000 Ordinary Shares of the Registrant under the Restricted Share Plan (the “Existing Registration Statement”).

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    All information required by Part I of Form S-8 to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act, and the Note to Part I of Form S-8. The document(s) containing the information specified in Part I will be delivered to employees of the Registrant and employees of subsidiaries of the Registrant participating in the Plans covered by this Registration Statement as required by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”). These documents and the documents incorporated herein by reference pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The reports or documents listed below have been filed with the Commission by the Registrant and are incorporated herein by reference:


    (a)
    The Registrant’s Annual Report on Form 20-F for the fiscal year ended December 31, 2024, filed with the Commission on February 14, 2025 (Commission File No. 001-38159) (the “Annual Report”);


    (b)
    All other reports filed pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) since the end of the fiscal year covered by the Annual Report (Commission File No. 001-38159); and


    (c)
    The description of the Ordinary Shares and ADSs contained in the Registrant’s Description of Securities Registered under Section 12 of the Exchange Act (filed as Exhibit 2.30 to the Annual Report (Commission File No. 001-38159)), and as amended by any subsequently filed amendments and reports updating such descriptions.


    All documents filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the date of this Registration Statement, and prior to the filing of a post-effective amendment that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold, will be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents. Reports on Form 6-K that the Registrant furnishes to the Commission will only be deemed incorporated by reference into this Registration Statement if, and to the extent, such Report on Form 6-K so states that it is incorporated by reference herein. Any statement contained in any document incorporated or deemed to be incorporated by reference herein will be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded will not be deemed, except as modified or superseded, to constitute a part of this Registration Statement.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Except as hereinafter set forth, there is no charter provision, by-law, contract, arrangement or statute under which any director or officer of the Registrant is insured or indemnified in any manner against any liability which he or she may incur in his or her capacity as such.

    Save as described below, under English law, any provision that purports to exempt a director of a company (to any extent) from any liability that would otherwise attach to him or her in connection with any negligence, default, breach of duty or breach of trust in relation to the company is void.

    Subject to certain exceptions, English law does not permit the Registrant to indemnify a director against any liability attaching to him or her in connection with any negligence, default, breach of duty or breach of trust in relation to the Registrant. The exceptions allow the Registrant to: (1) purchase and maintain director and officer insurance insuring its directors or the directors of an “associated company” (i.e., a company that is a subsidiary of the Registrant) against any liability attaching in connection with any negligence, default, breach of duty or breach of trust owed to the company of which he or she is a director; (2) provide a qualifying third party indemnity provision which permits the Registrant to indemnify its directors and directors of an associated company in respect of proceedings brought by third parties (covering both legal costs and the amount of any adverse judgment), except for (a) the legal costs of an unsuccessful defense of criminal proceedings or civil proceedings brought by the company or an associated company, or the legal costs incurred in connection with certain specified applications by the director for relief where the court refuses to grant the relief, (b) fines imposed in criminal proceedings, and (c) penalties imposed by regulatory bodies; (3) loan funds to a director to meet expenditures incurred defending civil and criminal proceedings against him or her (even if the action is brought by the company itself), or expenditures incurred applying for certain specified relief, subject to the requirement that the loan must be on terms that it is repaid if the defense or application for relief is unsuccessful; and (4) provide a qualifying pension scheme indemnity provision, which allows the company to indemnify a director of a company that is a trustee of an occupational pension scheme against liability incurred in connection with such director’s activities as a trustee of the scheme (subject to certain exceptions).


    Under the Registrant’s articles of association, subject to the UK Companies Act 2006, the Registrant may do any or all of the following:


    ●
    indemnify to any extent any person who is or was a director, or a director of any associated company, directly or indirectly (including by funding any expenditure incurred or to be incurred by him or her) against any loss or liability, whether in connection with any proven or alleged negligence, default, breach of duty or breach of trust by him or her or otherwise, in relation to the Registrant or any associated company;


    ●
    indemnify to any extent any person who is or was a director of an associated company that is a trustee of an occupational pension scheme, directly or indirectly (including by funding any expenditure incurred or to be incurred by him or her) against any liability incurred by him or her in connection with the company’s activities as trustee of an occupational pension scheme; and


    ●
    purchase and maintain insurance for any person who is or was a director, or a director of any associated company, against any loss or liability or any expenditure he or she may incur, whether in connection with any proven or alleged negligence, default, breach of duty or breach of trust by him or her or otherwise, in relation to the Registrant or any associated company.

    Item 7. Exemption From Registration Claimed.

    Not applicable.

    Item 8. Exhibits.

    Exhibit Number
    Description
       
    4.1
    Articles of Association of British American Tobacco p.l.c. (incorporated herein by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 6-K (Commission File No. 001-38159) filed with the Commission on 19 April 2023).
     
     
    4.2
    Second Amended and Restated Deposit Agreement, dated as of 26 November 2018, by and among the Registrant, Citibank, N.A., as depositary bank, and all holders and beneficial owners of ADSs issued thereunder (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-8 (Reg. No. 333-237186) filed with the Commission on 16 March 2020).
     
     
    4.3
    Rules of the British American Tobacco Restricted Share Plan (incorporated herein by reference to Exhibit 4.6 to the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2023, filed with the Commission on 9 February 2024 (Commission File No. 001-38159).
     
     
    4.4
    Rules of the British American Tobacco Performance Share Plan.
       
    5.1
    Opinion of Herbert Smith Freehills Kramer LLP regarding legality of the British American Tobacco p.l.c. ordinary shares being registered pursuant to this Registration Statement.
     
     
    23.1
    Consent of KPMG LLP.
     
     
    23.2
    Consent of Herbert Smith Freehills Kramer LLP (included in Exhibit 5.1).
     
     
    24
    Power of Attorney (contained on the signature page to this Registration Statement).
     
     
    107
    Calculation of Filing Fee Table.



    Item 9. Undertakings.

    (a)          The undersigned Registrant hereby undertakes:

    1.          To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i)          To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii)          To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

    (iii)          To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    2.          That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.


    3.          To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b)          The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c)          Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.



    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in London, England, on August 1, 2025.

     
    BRITISH AMERICAN TOBACCO P.L.C.
           
     
    By:
    /s/ Soraya Benchikh
     
       
    Name:
    Soraya Benchikh
     
       
    Title:
    Chief Financial Officer
     

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears above and below hereby constitutes and appoints Krishnan Anand, Soraya Benchikh, Karen Guerra, Luc Jobin, Holly Keller Koeppel, Uta Kemmerich-Keil, Véronique Laury, Tadeu Marroco, Darrell Thomas, Serpil Timuray and Caroline Ferland, and each of them acting without the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for and in his or her name, place and stead, with full power and authority to act in any and all capacities in connection with a registration statement on Form S-8 (the “Registration Statement”) relating to the registration under the Securities Act of 1933, as amended (the “Securities Act”), of the ordinary shares of British American Tobacco p.l.c. (“BAT”), including, without limiting the generality of the foregoing, to execute the Registration Statement on his or her behalf as a director or officer of, or on behalf of, BAT, and any or all amendments or supplements thereto, including any or all pre- and post-effective amendments, whether on Form S-8 or otherwise, and any new registration statement related thereto, filed under Rule 462(a) of the Securities Act, and to file the same, with all exhibits thereto and other documents in connection therewith, including this power of attorney, with the Securities and Exchange Commission (the “SEC”), granting unto said attorneys-in-fact and each of them full power and authority to do and perform each and every act and thing requisite and necessary to be done or incidental to the performance and execution of the powers herein expressly granted and that may be required to enable BAT to comply with the Securities Act or the Securities Exchange Act of 1934, as amended, and any rules, regulations or requirements of the SEC in respect thereof, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that either said attorney-in-fact or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities indicated below on August 1, 2025.


         
    Signature
     
    Title
         
         
    /s/ Krishnan Anand    
    Krishnan Anand
     
    Non-Executive Director
         
         
    /s/ Soraya Benchikh    
    Soraya Benchikh
     
    Executive Director—Chief Financial Officer
    (Principal Financial and Accounting Officer)
         
         
    /s/ Karen Guerra    
    Karen Guerra
     
    Non-Executive Director
         
         
    /s/ Luc Jobin    
    Luc Jobin
     
    Chair
         
         
    /s/ Holly Keller Koeppel    
    Holly Keller Koeppel
     
    Senior Independent Director
         
         
    /s/ Uta Kemmerich-Keil    
    Uta Kemmerich-Keil
     
    Non-Executive Director
         
         
    /s/ Véronique Laury    
    Véronique Laury
     
    Non-Executive Director
         
         
    /s/ Tadeu Marroco    
    Tadeu Marroco
     
    Executive Director—Chief Executive
    (Principal Executive Officer)
         
         
    /s/ Darrell Thomas    
    Darrell Thomas
     
    Non-Executive Director
         
         
    /s/ Serpil Timuray    
    Serpil Timuray
     
    Non-Executive Director
         
         
    /s/ Donald J. Puglisi    
    Donald J. Puglisi
    Managing Director, Puglisi & Associates
     
    Authorized Representative in the United States


    Get the next $BTI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTI

    DatePrice TargetRatingAnalyst
    7/9/2025Buy
    Jefferies
    4/30/2025Buy
    BofA Securities
    1/27/2025Neutral → Buy
    UBS
    10/3/2024$33.00Overweight → Underweight
    Morgan Stanley
    1/23/2024Neutral
    UBS
    11/1/2023$38.00Overweight
    Morgan Stanley
    9/25/2023Buy
    Citigroup
    9/1/2023Buy → Hold
    Argus
    More analyst ratings

    $BTI
    SEC Filings

    View All

    SEC Form S-8 filed by British American Tobacco Industries p.l.c.

    S-8 - British American Tobacco p.l.c. (0001303523) (Filer)

    8/1/25 10:03:02 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by British American Tobacco Industries p.l.c.

    6-K - British American Tobacco p.l.c. (0001303523) (Filer)

    8/1/25 8:24:00 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by British American Tobacco Industries p.l.c.

    6-K - British American Tobacco p.l.c. (0001303523) (Filer)

    7/31/25 9:26:30 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Charlotte's Web Reports 2024 First Quarter Financial Results

    LOUISVILLE, Colo., May 8, 2024 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full-spectrum hemp extract wellness products, today reported financial results for the first quarter ended March 31, 2024. "The first quarter of 2024 started slowly in terms of sales volume. This is being addressed with solid progress in our 'True North' turnaround initiatives," said Bill Morachnick, Chief Executive Officer of Charlotte's Web. "For example, our legacy e-commerce platform limits our ability to be agile

    5/8/24 7:07:00 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    British American Tobacco p.l.c investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises British American Tobacco p.l.c (NYSE:BTI) investors that a lawsuit was filed on behalf of investors that purchased BTI securities between February 9, 2023 and December 6, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing cla

    1/24/24 6:21:08 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    Organigram Announces C$124.6 Million Investment from BAT and Creation of "Jupiter" Strategic Investment Pool

    Organigram and BAT deepen partnership through C$124.6 million investment with 38.7 million shares to be issued over three tranches Organigram to use C$83.1 million of the investment to create "Jupiter," a strategic investment pool designed to expand Organigram's geographic footprint and capitalize on emerging growth opportunities C$41.5 million of the investment will be used for general corporate purposes Investment enhances strategic Product Development Collaboration between BAT and Organigram, which focuses on cutting-edge R&D and product innovation BAT to increase voting Common Share ownership position to 30% and overall equity interest to 45% (including non-voting Class A P

    11/6/23 6:00:00 AM ET
    $BTI
    $OGI
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on British American Tobacco

    Jefferies resumed coverage of British American Tobacco with a rating of Buy

    7/9/25 8:26:14 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    BofA Securities resumed coverage on British American Tobacco

    BofA Securities resumed coverage of British American Tobacco with a rating of Buy

    4/30/25 9:01:21 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    British American Tobacco upgraded by UBS

    UBS upgraded British American Tobacco from Neutral to Buy

    1/27/25 7:35:54 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Bt De Investments Inc.

    3 - British American Tobacco p.l.c. (0001303523) (Reporting)

    11/23/22 4:29:54 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTI
    Leadership Updates

    Live Leadership Updates

    View All

    British American Tobacco p.l.c investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises British American Tobacco p.l.c (NYSE:BTI) investors that a lawsuit was filed on behalf of investors that purchased BTI securities between February 9, 2023 and December 6, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing cla

    1/24/24 6:21:08 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    Charlotte's Web Announces Appointment of Bill Morachnick as Chief Executive Officer

    Provides Update on Majority Voting Policy Process LOUISVILLE, Colo., Sept. 13, 2023 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") is pleased to announce the appointment of William (Bill) Morachnick who has joined the Company as its Chief Executive Officer. Mr. Morachnick has also been appointed to the Company's Board of Directors as a non-independent director. He replaces CEO Jacques Tortoroli who has elected to resign from his roles at Charlotte's Web.  CWEB) (OTCQX:CWBHF):. The World's Most Trusted Hemp Extract and Official CBD of Major League Baseball (MLB). (C

    9/13/23 7:07:00 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    GREENBUTTS APPPOINTS FORMER BIG TOBACCO EXECUTIVE AS CHIEF STRATEGY OFFICER

    SAN DIEGO, Calif., June 22, 2022 /PRNewswire/ - Greenbutts, LLC (the "Company" or "Greenbutts") is pleased to announce the appointment of Luis Sanches as the Company's Chief Strategy Officer effective immediately. Luis is a Senior Corporate Executive with more than 30 years of international, cross functional and cross-cultural experience responsible for managing business teams, supporting growth, and leading transformations across multiple geographies such as Australasia, North and South America, and Europe. He was previously the Senior Vice President of R&D for Reynolds Ameri

    6/22/22 2:34:00 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by British American Tobacco Industries p.l.c. (Amendment)

    SC 13G/A - British American Tobacco p.l.c. (0001303523) (Subject)

    2/9/24 6:03:23 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by British American Tobacco Industries p.l.c. (Amendment)

    SC 13G/A - British American Tobacco p.l.c. (0001303523) (Subject)

    2/9/24 5:46:32 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by British American Tobacco Industries p.l.c. (Amendment)

    SC 13G/A - British American Tobacco p.l.c. (0001303523) (Subject)

    1/26/24 4:56:06 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTI
    Financials

    Live finance-specific insights

    View All

    Charlotte's Web Reports 2024 First Quarter Financial Results

    LOUISVILLE, Colo., May 8, 2024 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full-spectrum hemp extract wellness products, today reported financial results for the first quarter ended March 31, 2024. "The first quarter of 2024 started slowly in terms of sales volume. This is being addressed with solid progress in our 'True North' turnaround initiatives," said Bill Morachnick, Chief Executive Officer of Charlotte's Web. "For example, our legacy e-commerce platform limits our ability to be agile

    5/8/24 7:07:00 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    Charlotte's Web Reports 2023 Second Quarter Financial Results

    Encouraging CBD regulatory progress in CongressNet revenue of $16.0M vs. $18.9M YoYCash increased to $61.7M LOUISVILLE, Colo., Aug. 10, 2023 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full spectrum hemp extract wellness products, today reported financial results for the second quarter ended June 30, 2023.  Regulatory Update During the second quarter, the U.S. Food and Drug Administration ("FDA") committed to "work at speed" with Congress to resolve a regulatory pathway for hemp-derived CBD.

    8/10/23 7:33:00 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    Charlotte's Web Reports 2023 First Quarter Financial Results

    Net cash of $61MNet revenue of $17M decreased 12.1% YoY14% YoY reduction in operating expenses LOUISVILLE, Colo., May 12, 2023 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full spectrum hemp extract wellness products, today reported financial results for the first quarter ended March 31, 2023. "In the first quarter, we maintained prudent cost controls to balance softness in the CBD category due to the unregulated environment. We successfully reduced operating expenses by 14% on a year-over-ye

    5/12/23 7:05:00 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care